Tight junction proteins expression and modulation in immune cells and multiple sclerosis.
Bottom Line: Interestingly, claudin 1 protein levels were elevated also in PBLs of patients with type 1 diabetes (T1D).Following glucocorticoid treatment of MS patients in relapse, RNA levels of JAM3 and CLDN5 and claudin 5 protein levels in PBLs decreased.Furthermore, a correlation between CLDN5 pre-treatment levels and clinical response phenotype to interferon-β therapy was detected.
Affiliation: Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.Show MeSH
Related in: MedlinePlus
Mentions: Following our observations that in vitro activation of leukocytes modulates TJP expression, ex vivo expression analysis was performed for PBLs from MS patients, OND, T1D and healthy control individuals. Claudin 1 protein levels were significantly higher in MS patients in relapse when compared to healthy controls (3.3-fold change, PB= 1.5 × 10−5), and to patients in remission (3.1-fold change, PB= 5.9 × 10−4; Fig. 3A). Claudin 1 protein levels were also higher in the T1D group when compared to healthy controls (2.4-fold change, PB = 7 × 10−5), but not in the OND group. The higher levels of claudin 1 observed in PBLs from the active autoimmune diseases, MS and T1D, is in line with the effects observed for the in vitro activations the expression of this protein in leukocytes. The RNA levels of CLDN1 could not be reliably analysed, because its transcript appeared to be very labile using the study’s standard RNA extraction procedures and in the quantitative RT-PCR assay (as opposed to the qualitative assay used in the preliminary screen) gave very variable results.
Affiliation: Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.